Oncology

The recent acquisition of Relief Therapeutics by Sonnet BioTherapeutics will surely fuel the growth of Chemotherapy-Induced Peripheral Neuropathy (CIPN) therapy market. Sonnet plans to commence the development of its promising candidate SON-080 for CIPN treatment. Peripheral Neuropathy is a set of complications caused as a result of damage to the distant nerves away from the brain and spinal cord. Cancer patients undergoing chemotherapy usually suffer from CIPN. Chemotherapy along with other drugs are potentials caused by the damage to the distant nerves in the Cancer patients. This is one of the disabling side effects of cancer treatment. CIPN can hamper routine acti...